Señales en vivo de 4569.T | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 02:15):

Stats
Volumen de hoy	84 900.00
Volumen promedio	69 440.00
Capitalización de mercado	105.02B
EPS	¥0 ( 2024-02-05 )
Próxima fecha de ganancias	( ¥0 ) 2024-05-08
Last Dividend	¥32.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	24.63
ATR14	¥1.224 (0.07%)

Volumen Correlación

Largo: 0.12 (neutral)

Corto: 0.91 (very strong)

Signal:(59.072) Expect same movement, but be aware

KYORIN Holdings, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

KYORIN Holdings, Inc. Correlación - Moneda/Commodity

0.74
( moderate )

0.86
( strong )

-0.19
( neutral )

0.86
( strong )

-0.31
( neutral )

-0.87
( strong negative )

KYORIN Holdings, Inc. Finanzas

Annual	2022
Ingresos:	¥113.27B
Beneficio Bruto:	¥50.17B (44.29 %)
EPS:	¥82.42

FY	2022
Ingresos:	¥113.27B
Beneficio Bruto:	¥50.17B (44.29 %)
EPS:	¥82.42

FY	2022
Ingresos:	¥105.53B
Beneficio Bruto:	¥49.44B (46.85 %)
EPS:	¥68.62

FY	2021
Ingresos:	¥102.90B
Beneficio Bruto:	¥51.63B (50.17 %)
EPS:	¥106.99

Financial Reports:

No articles found.

KYORIN Holdings, Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥20.00 (N/A)	¥0 (N/A)	¥32.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

KYORIN Holdings, Inc. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.34 - Stable (13.14%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥10.00	2006-09-26
Last Dividend	¥32.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	35	--
Total Paid Out	¥862.50	--
Avg. Dividend % Per Year	0.00%	--
Score	3.6	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.34
Div. Directional Score	7.48	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

3.60

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8285.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7673.T	Ex Dividend Junior	2024-05-30	Annually	0.00%
6855.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6203.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
4929.T	Ex Dividend Junior	2024-03-18	Annually	0.00%
4099.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%
3315.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
2384.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
9312.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
8043.T	Ex Dividend Junior	2024-03-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0356	1.500	9.29	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0238	1.200	9.21	10.00	[0 - 0.3]
returnOnEquityTTM	0.0339	1.500	-0.735	-1.102	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.53	0.800	2.34	1.871	[1 - 3]
quickRatioTTM	1.327	0.800	6.90	5.52	[0.8 - 2.5]
cashRatioTTM	0.402	1.500	8.88	10.00	[0.2 - 2]
debtRatioTTM	0.116	-1.500	8.06	-10.00	[0 - 0.6]
interestCoverageTTM	75.14	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.164	-1.500	9.34	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.429	1.000	6.18	6.18	[0.2 - 0.8]
operatingProfitMarginTTM	0.0408	1.000	-1.185	-1.185	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.405	1.000	8.86	8.86	[0.2 - 2]
assetTurnoverTTM	0.670	0.800	8.87	7.10	[0.5 - 2]
Total Score				10.62

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.65	1.000	7.61	0	[1 - 100]
returnOnEquityTTM	0.0339	2.50	-0.472	-1.102	[0.1 - 1.5]
freeCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.84	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.226	1.500	5.16	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0702	1.000	-0.745	0	[0.1 - 0.5]
Total Score				4.34

KYORIN Holdings, Inc.

KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.